Should You Be Worried After Bristol-Myers Squibb's Q3 Results?
It's been an up-and-down kind of year for Bristol-Myers Squibb (NYSE: BMY). Early in 2017, investors were concerned after the company opted not to pursue accelerated approval for a combination of Opdivo and Yervoy in first-line non-small cell lung cancer (NSCLC). Those worries largely evaporated, though, and BMS stock eventually went on to generate nice year-to-date gains.
Now, however, worries are resurfacing. Bristol-Myers Squibb announced its third-quarter results before the market opened on Thursday, with an immediate drop in its share price. Here are the highlights of those results -- and whether investors really need to be concerned this time around.
Image source: Getty Images.
Source: Fool.com
Bristol-Myers Squibb Stock
€46.46
11.400%
We see a rather positive sentiment for Bristol-Myers Squibb with 8 Buy predictions and 2 Sell predictions.
With a target price of 70 € there is a hugely positive potential of 50.67% for Bristol-Myers Squibb compared to the current price of 46.46 €.
